AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17580194 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (n = 13)
Number of subjects: 38
Study 15857272 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (25 g/day)
Number of subjects: 32
Study 15857272 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk protein isolate (25 g/day)
Number of subjects: 32
Study 15857272 — intervention group
Group type: COMPARATOR
Intervention: Step I diet (low-fat, high-fiber)
Number of subjects: 32
Study 12038492 — intervention group
Group type: EXPERIMENTAL
Intervention: Text structural variables (on vs. off the causal chain, active vs. static information, hierarchical structure)
Number of subjects: 24
Study 12038492 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in the type of information contained in the text
Number of subjects: 24
Study 10401657 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage within 10 days
Number of subjects: 60
Study 10401657 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 60
Study 10401657 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 60
Study 7758568 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter at the mouth (Spirobac)
Number of subjects: 0
Study 7758568 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 0
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurement Scales (AIMS)
Number of subjects: 38
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Index (FSI)
Number of subjects: 38
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 38
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Well Being (IWB)
Number of subjects: 38
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile (SIP)
Number of subjects: 38
Study 2366602 — intervention group
Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 38
Study 518245 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0
Study 518245 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term interpersonal psychotherapy
Number of subjects: 0
Study 518245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and psychotherapy
Number of subjects: 0
Study 518245 — intervention group
Group type: COMPARATOR
Intervention: Nonscheduled treatment control group
Number of subjects: 0
Study 31161592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention app (n=25)
Number of subjects: 45
Study 31161592 — intervention group
Group type: COMPARATOR
Intervention: Control app (n=20)
Number of subjects: 45
Study 28732834 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler reminders via SmartTrack adherence monitors (Adherium Ltd)
Number of subjects: 18
Study 26040221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 220
Study 26040221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser
Number of subjects: 220
Study 26040221 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 220
Study 26040221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy and ranibizumab + laser
Number of subjects: 220
Study 26040221 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile
Number of subjects: 220
Study 24066704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 4 months, delivered in 20 individual outpatient sessions.
Number of subjects: 60
Study 24066704 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition (C).
Number of subjects: 60
Study 24066704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT).
Number of subjects: 60
Study 21895039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral, direct Factor Xa inhibitor)
Number of subjects: 0
Study 21895039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once daily) in patients with AF with creatinine clearance of 30-49 mL/min
Number of subjects: 0
Study 21895039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time
Number of subjects: 0
Study 19304928 — intervention group
Group type: EXPERIMENTAL
Intervention: DOiT intervention
Number of subjects: 0
Study 18214218 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions to enhance adherence to ART, specific interventions not detailed in the abstract.
Number of subjects: 0
Study 18214218 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized short-term interventions tested by randomized controlled trials.
Number of subjects: 0
Study 18214218 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term programs tailored to the patient's needs.
Number of subjects: 0
Study 15106686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior alveolar block/long buccal infiltration anesthesia
Number of subjects: 101
Study 15106686 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration/intrapapillary injection
Number of subjects: 101
Study 11758006 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study 11758006 — intervention group
Group type: COMPARATOR
Intervention: Sitting with CPAP of 8 cm H2O
Number of subjects: 10
Study 11758006 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10
Study 9750937 — intervention group
Group type: EXPERIMENTAL
Intervention: A-308 genotype (T2)
Number of subjects: 78
Study 9750937 — intervention group
Group type: EXPERIMENTAL
Intervention: A-308 transition genotype
Number of subjects: 78
Study 9750937 — intervention group
Group type: EXPERIMENTAL
Intervention: A-238 transition genotype
Number of subjects: 78
Study 8525757 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment Program (BHG) including deep muscle relaxation, peripheral temperature Biofeedback, and anxiety management training
Number of subjects: 21
Study 3396576 — intervention group
Group type: EXPERIMENTAL
Intervention: HFHP diet (low CHO, high fat, high protein)
Number of subjects: 6
Study 3396576 — intervention group
Group type: COMPARATOR
Intervention: N diet (normal diet)
Number of subjects: 6
Study 3396576 — intervention group
Group type: COMPARATOR
Intervention: HCLF diet (high CHO, low fat, normal protein)
Number of subjects: 6
Study 31445509 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed pediatric zirconia crowns (EZCrowns, Sprig Oral Health Technologies)
Number of subjects: 101
Study 31445509 — intervention group
Group type: COMPARATOR
Intervention: Preformed pediatric stainless steel crowns (ESPE, 3M)
Number of subjects: 101
Study 28841916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (four cycles FOLFIRINOX) followed by resection
Number of subjects: 90
Study 28841916 — intervention group
Group type: COMPARATOR
Intervention: Surgery first (control group) followed by adjuvant chemotherapy (six cycles gemcitabine and capecitabine)
Number of subjects: 90
Study 25662348 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 85
Study 25662348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 23726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg once daily for 14 days
Number of subjects: 24
Study 23726291 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (SMV) 80mg administered alone
Number of subjects: 24
Study 21212398 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door stroke case ascertainment
Number of subjects: 2437
Study 21212398 — intervention group
Group type: COMPARATOR
Intervention: Hospital surveillance
Number of subjects: 2437
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Self-Examination (BSE)
Number of subjects: 425
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Breast Examination (CBE)
Number of subjects: 425
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 425
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer knowledge
Number of subjects: 425
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of breast cancer screening (BCS)
Number of subjects: 425
Study 18712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular visit with a physician
Number of subjects: 425
Study 18712963 — intervention group
Group type: COMPARATOR
Intervention: Age, family history of breast cancer, marital status, health insurance
Number of subjects: 425
Study 16098942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillations at 3 Hz
Number of subjects: 0
Study 16098942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole image motion
Number of subjects: 0
Study 16098942 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movements during image motion
Number of subjects: 0
Study 12554315 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeted at both patient and spouse
Number of subjects: 24
Study 12554315 — intervention group
Group type: COMPARATOR
Intervention: Patient education intervention targeted at only the patient
Number of subjects: 24
Study 11129675 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Lp(a) levels
Number of subjects: 202
Study 9396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin-ticlopidine-aspirin
Number of subjects: 0
Study 9396639 — intervention group
Group type: COMPARATOR
Intervention: Warfarin regimen
Number of subjects: 0
Study 9396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ticlopidine, aspirin)
Number of subjects: 0
Study 9396639 — intervention group
Group type: COMPARATOR
Intervention: Phenocoumaron and aspirin
Number of subjects: 0
Study 8450381 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (3 mg/L)
Number of subjects: 3
Study 8450381 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (6 mg/L)
Number of subjects: 3
Study 8450381 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 3
Study 3312212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid (Aristocort A)
Number of subjects: 159
Study 3312212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E
Number of subjects: 159
Study 3312212 — intervention group
Group type: COMPARATOR
Intervention: Base cream carrier
Number of subjects: 159
Study 30466845 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with posterior/lateral LV lead location
Number of subjects: 797
Study 30466845 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with anterior LV lead location
Number of subjects: 797
Study 30466845 — intervention group
Group type: COMPARATOR
Intervention: CRT-D (any lead location)
Number of subjects: 797
Study 30466845 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with apical LV lead location
Number of subjects: 797
Study 30466845 — intervention group
Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 797
Study 27007650 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless percutaneous nephrolithotomy (PCNL)
Number of subjects: 84
Study 27007650 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (PCNL)
Number of subjects: 84
Study 25608093 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based learning
Number of subjects: 0
Study 25608093 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom learning
Number of subjects: 0
Study 23857197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg intravenous midazolam (high dose)
Number of subjects: 100
Study 23857197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.035 mg/kg intravenous midazolam (low dose)
Number of subjects: 100
Study 23857197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23857197 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 100
Study 19961264 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampanel 50 mg p.o. t.i.d
Number of subjects: 59
Study 19961264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 18086066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (1 mg x kg(‐1)) and pethidine (1 mg x kg(‐1)) in adrenaline 1:200,000
Number of subjects: 80
Study 18086066 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 80
Study 18086066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and pethidine
Number of subjects: 80
Study 16896953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 0
Study 16896953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.1 mg)
Number of subjects: 0
Study 16896953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14633807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522
Study 14633807 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 522
Study 10928235 — intervention group
Group type: EXPERIMENTAL
Intervention: IAsp (0.15 IU/kg body weight) immediately before the meal
Number of subjects: 25
Study 10928235 — intervention group
Group type: COMPARATOR
Intervention: Actrapid (0.15 IU/kg) immediately before the meal (Act0)
Number of subjects: 25
Study 10928235 — intervention group
Group type: COMPARATOR
Intervention: Actrapid (0.15 IU/kg) 30 minutes before the meal (Act-30)
Number of subjects: 25
Study 8616414 — intervention group
Group type: EXPERIMENTAL
Intervention: n of 1 trials (theophylline)
Number of subjects: 31
Study 8616414 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (theophylline stopped and resumed based on dyspnoea)
Number of subjects: 31
Study 1451921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivida cream applied twice daily for 120 days
Number of subjects: 30
Study 1451921 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 6087475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendamistate (100 mg)
Number of subjects: 9
Study 6087475 — intervention group
Group type: COMPARATOR
Intervention: Guar (5 g)
Number of subjects: 9
Study 6087475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29995679 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hospitals (≥21 surgeries/year)
Number of subjects: 494
Study 29995679 — intervention group
Group type: COMPARATOR
Intervention: Low-volume hospitals (1-20 surgeries/year)
Number of subjects: 494
Study 28930060 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer BI
Number of subjects: 555
Study 28930060 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist BI
Number of subjects: 555
Study 25733640 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral protein feeding (hypocaloric-hyponitrogenous)
Number of subjects: 10
Study 25733640 — intervention group
Group type: COMPARATOR
Intervention: Stable parenteral amino acid supply (n = 7)
Number of subjects: 10
Study 24570635 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision CTR
Number of subjects: 0
Study 24570635 — intervention group
Group type: COMPARATOR
Intervention: Two-incision CTR
Number of subjects: 0
Study 21971483 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1999
Study 21971483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypothyroidism
Number of subjects: 1999
Study 21971483 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 1999
Study 21971483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hyperthyroidism
Number of subjects: 1999
Study 21971483 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive TPOAb
Number of subjects: 1999
Study 19609054 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20-80 mg/d)
Number of subjects: 51
Study 19609054 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (2-8 mg/d)
Number of subjects: 51
Study 17465659 — intervention group
Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 30 vol% filler
Number of subjects: 60
Study 17465659 — intervention group
Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 50 vol% filler
Number of subjects: 60
Study 17465659 — intervention group
Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 70 vol% filler
Number of subjects: 60
Study 17465659 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfilled UDMA adhesive
Number of subjects: 60
Study 17465659 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 15672598 — intervention group
Group type: EXPERIMENTAL
Intervention: PsychoedPlusMed (psychoeducational intervention combined with sildenafil)
Number of subjects: 0
Study 15672598 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil only (control group)
Number of subjects: 0
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set group (SSG)
Number of subjects: 99
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-set group (MSG)
Number of subjects: 99
Study 16003539 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 99
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE II genotype in MST group
Number of subjects: 99
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE DD genotype in SSG and MSG
Number of subjects: 99
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE ID genotype in SSG
Number of subjects: 99
Study 16003539 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE DD genotype in both training groups
Number of subjects: 99
Study 10690150 — intervention group
Group type: COMPARATOR
Intervention: saline i.v. (group I, n = 62)
Number of subjects: 242
Study 10690150 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 2.5 mg i.v. (group 2, n = 60)
Number of subjects: 242
Study 10690150 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v. (group 3, n = 57)
Number of subjects: 242
Study 10690150 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 2.5 mg with ondansetron 4 mg i.v. (group 4, n = 63)
Number of subjects: 242
Study 10690150 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol and ondansetron combination
Number of subjects: 242
Study 8920850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion at 40 mg/kg for 4 hours before endotoxin challenge (4 ng/kg)
Number of subjects: 0
Study 8920850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion
Number of subjects: 0
Study 8920850 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytes isolated from rHDL-treated whole blood
Number of subjects: 0
Study 1864205 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/day
Number of subjects: 4524
Study 1864205 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4524
Study 6356758 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (4, 5, 6, 7‐tetrahydroisoxazolo (5,4‐) pyridin‐3‐ol)
Number of subjects: 6
Study 6356758 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study 30009423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing (third-person perspective)
Number of subjects: 139
Study 30009423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing (competent media character perspective)
Number of subjects: 139
Study 30009423 — intervention group
Group type: COMPARATOR
Intervention: Self-immersed perspective
Number of subjects: 139
Study 30009423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-distancing)
Number of subjects: 139
Study 29022411 — intervention group
Group type: EXPERIMENTAL
Intervention: Notched noise (1000‐12,000Hz notched within a 1‐octave range centred around the tinnitus pitch match frequency)
Number of subjects: 30
Study 29022411 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched noise (1‐octave wide band of noise centred around the PM frequency)
Number of subjects: 30
Study 29022411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low frequency noise 250‐700Hz)
Number of subjects: 30
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus hydroxychloroquine plus sulphasalazine plus low dose prednisone (arm 1)
Number of subjects: 610
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab (arm 2)
Number of subjects: 610
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission group (patients who achieved early DAS-remission after 4 months)
Number of subjects: 610
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 610
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 610
Study 26794605 — intervention group
Group type: EXPERIMENTAL
Intervention: UA patients
Number of subjects: 610
Study 24459683 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-iodine
Number of subjects: 12
Study 24459683 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study 22699168 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation education
Number of subjects: 60
Study 22699168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 20236548 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated split virion influenza vaccine (TIV)
Number of subjects: 0
Study 20236548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17394970 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI)
Number of subjects: 13819
Study 17394970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GPI
Number of subjects: 13819
Study 17394970 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin monotherapy (plus provisional GPI)
Number of subjects: 13819
Study 17394970 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 13819
Study 15760638 — intervention group
Group type: EXPERIMENTAL
Intervention: MELAS patients
Number of subjects: 0